Bossowski A, Urban M, Gardziejczyk M, Kitszel A, Rogowski F, Sobotko J
2nd Department of Children's Diseases, Medical Academy of Bialystok, Poland.
J Pediatr Endocrinol Metab. 2000 Sep-Oct;13(8):1067-72. doi: 10.1515/jpem.2000.13.8.1067.
Serum levels of sICAM-1, sVCAM-1 and sP-selectin were determined in patients with Graves' disease before and after 8 weeks and 24 months of methimazole therapy, in levothyroxine suppressed patients with non-toxic nodular goiter, and in a group of healthy controls, to elucidate the relationship to circulating antithyroid antibodies and possible role of soluble adhesion molecules as markers of inflammatory activity. sICAM-1, sVCAM-1, and sP-selectin in patients with untreated hyperthyroidism were markedly elevated compared with controls. After 8 weeks of methimazole treatment, the concentrations of these molecules dropped, but were still significantly higher than in healthy children. In patients with clinical and biochemical remission after 24 months of therapy, sICAM-1 values were on the verge of significance, but still higher than in the control group, whereas serum levels of sVCAM-1 and sP-selectin had normalized. Slightly higher serum sICAM-1 values were observed in patients with non-toxic nodular goiter compared with healthy children.
测定了格雷夫斯病患者在接受甲巯咪唑治疗8周和24个月前后、左甲状腺素抑制的非毒性结节性甲状腺肿患者以及一组健康对照者的血清可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)和可溶性P选择素水平,以阐明其与循环抗甲状腺抗体的关系以及可溶性黏附分子作为炎症活动标志物的可能作用。未治疗的甲状腺功能亢进患者的sICAM-1、sVCAM-1和sP选择素水平与对照组相比显著升高。甲巯咪唑治疗8周后,这些分子的浓度下降,但仍显著高于健康儿童。治疗24个月后达到临床和生化缓解的患者,sICAM-1值接近显著水平,但仍高于对照组,而sVCAM-1和sP选择素的血清水平已恢复正常。与健康儿童相比,非毒性结节性甲状腺肿患者的血清sICAM-1值略高。